What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature built on Fundamental Research Corp's institutional-grade valuation methodology. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Abeona Therapeutics Inc. stock price today?

Abeona Therapeutics Inc. (ABEO) is currently trading at $7.4 USD on NASDAQ. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Abeona Therapeutics Inc. do?

Abeona Therapeutics Inc. operates in the Biotechnology sector within Healthcare. Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its l...

How do I analyze Abeona Therapeutics Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of Abeona Therapeutics Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Abeona Therapeutics Inc. financial statements?

Access Abeona Therapeutics Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC applies its proprietary valuation model to public stock analysis, so fair value estimates rest on a rigorous, data-driven methodology rather than a consensus average. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Abeona Therapeutics Inc.

Industry

Biotechnology

Sector

Healthcare

CEO

Vishwas Seshadri

Headquarters

1330 Avenue of the Americas, Cleveland, NY, US

Industry

Biotechnology

Sector

Healthcare

CEO

Vishwas Seshadri

Headquarters

1330 Avenue of the Americas, Cleveland, NY, US

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Abeona Therapeutics Inc.

ABEO•NASDAQ

Abeona Therapeutics Inc.

ABEO•NASDAQ

Market cap

$421.76M

Sentiment

Your view on ABEO

Mkt Cap

$421.76M

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Abeona Therapeutics Inc.

Industry: Biotechnology
Sector: Healthcare
CEO: Vishwas Seshadri
Headquarters: 1330 Avenue of the Americas, Cleveland, NY, US

Industry: Biotechnology
Sector: Healthcare
CEO: Vishwas Seshadri
Headquarters: 1330 Avenue of the Americas, Cleveland, NY, US

Description

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Abeona Therapeutics Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Abeona Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Abeona Therapeutics Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Abeona Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Abeona Therapeutics Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Abeona Therapeutics Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Abeona Therapeutics Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Abeona Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Abeona Therapeutics Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Abeona Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Abeona Therapeutics Inc.. Press releases and market coverage, newest first.

News

Latest Market News